Nicholas Whiting1,2, Jingzhe Hu1,3, Shivanand Pudakalakatti1, Caitlin McCowan1,3, Hyeonglim Seo4, Youngbok Lee4, and Pratip Bhattacharya1
1The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2Rowan University, Glassboro, NJ, United States, 3Rice University, Houston, TX, United States, 4Hanyang University, Ansan, Republic of Korea
Synopsis
Hyperpolarized silicon microparticles
have been previously demonstrated as in vivo MRI contrast agents;
unfortunately, their large size and decreased mobility present limitations for targeted molecular imaging. While nanoscale silicon particles can also be
hyperpolarized, their signal enhancement is typically limited by a low
concentration of endogenous electrons. As such, no studies to date have
demonstrated in vivo 29Si MRI of hyperpolarized nano-scale silicon. We
demonstrate improved 29Si hyperpolarization with the addition of an exogenous
radical species to both solid and mesoporous nanoparticle samples (30-300 nm
diameter), which increases 29Si hyperpolarization and allows in vivo imaging of
silicon nanoparticles.
Introduction
Nano-scale silicon particles have potential utility as targeted
molecular imaging agents due to their biocompatibility and simple surface
chemistry that is amenable to drug loading and targeting [1,2]. Given that 29Si
is MR-active (I=1/2), silicon nanoparticles (SiNPs) may be developed as in vivo
MR contrast agents. Indeed, the ability to perform in vivo 29Si MRI has been
demonstrated in silicon microparticles that are hyperpolarized using dynamic
nuclear polarization (DNP) [3,4]. Unfortunately, due to their large size and
lack of mobility, micro-scale silicon particles have limitations for targeted
molecular imaging, especially when vascular delivery is needed [5]. While some
preliminary studies have shown that nano-scale silicon particles can also be
hyperpolarized via DNP [5-7], there have been no demonstrated in vivo studies
to date. Indeed, in a direct comparison, nanoscale silicon particles have been
shown to provide a fraction of the HP 29Si MR signal (~30x less) compared to
microscale particles [5]. Here we report our efforts to improve DNP of
nanoscale silicon particles through the addition of an exogenous radical species
((2,2,6,6-Tetramethylpiperidin-1-yl)oxyl, or ‘TEMPO’), which provides
additional free electrons to improve the efficiency of 29Si DNP. Initial
electron spin resonance (ESR) studies showed that microscale particles
contained nearly 10x more available electrons compared to the nanoscale
particles; this is likely due to an increase in internal defects and amorphous
regions of the micro-scale particles. By titrating in different concentrations
of TEMPO, we were able to maximize the achievable 29Si MR signal, thus allowing
for in vivo imaging of nanoscale silicon particles. Furthermore, we also applied the addition of TEMPO to
interrogate mesoporous silicon nanoparticles, which could be further developed as
drug delivery theranostic agents.Methods
Solid silicon particles ranging from 30 to 200 nm diameter were
commercially procured and used as received. Mesoporous silicon particles were
synthesized using a modified Stober method to create silica particles, followed
by reduction with Mg at high temperatures and pressures; this resulted in ~300
nm diameter spherical mesoporous SiNPs with ~10 nm diameter pores. These
mesoporous SiNPs were surface-functionalized with 3-aminopropyl-triethoxysilane
(APTES). Particle samples (~50 mg) were dissolved in a 1:1 mixture of D2O and
DMSO, with varying concentrations of TEMPO radical mixed in (total sample
volume ~130 µL). The particles were hyperpolarized using a laboratory-constructed 29Si
solid-state DNP device [5]; imaging and spectroscopy studies were performed at
room temperature on a 7T small animal MRI. Co-registered [1H:29Si]
MRI was performed using a dual-tuned 29Si/1H Litz coil: in vivo 29Si imaging used a
coronal RARE sequence (α = 90°; TR/TE: 60 ms/1.8 ms; 6.4 cm FOV; 2 mm resolution), while 1H
imaging utilized a coronal RARE scan (α = 90°), TR/TE: 1927 ms/9.5 ms with a RARE
factor of 8; 6.4 cm FOV (0.25 mm resolution) and 4 averages. 29Si spectroscopy
utilized a variable tipping angle pulse to interrogate the hyperpolarization buildup
or decay values.Results
ESR studies show that adding TEMPO to the nanoparticle solutions
significantly improved the pool of available free electrons for DNP. This
translated to increased 29Si MR signals following DNP with added radical (Figure
1); these improvements ranged from 1.5x to more than 6x compared to DNP without
TEMPO. Adding radical slightly hastened 29Si T1 decay; under conditions of
optimal TEMPO concentration, T1 values decreased by ~25% for all nanoparticle
sizes. Despite this faster T1, 29Si MR signal was sufficiently improved to
warrant inclusion of TEMPO (i.e., increases in 29Si hyperpolarization overcame
losses from T1). This allowed, for the first time, in vivo 29Si MRI of
hyperpolarized nano-scale silicon particles (Figure 2), as well as studies of
mesoporous silicon nanoparticles (Figures 3-5).Discussion
The ability to considerably improve 29Si hyperpolarization in nanoscale
solid and mesoporous particles through the addition of exogenous radicals is a
significant step forward in their development as targeted imaging agents. We
present the first demonstration of in vivo imaging of nanoscale silicon
particles, as well as the first reported hyperpolarization studies involving
mesoporous silicon nanoparticles. The added TEMPO was not removed prior to
injection into the mouse models, and no ill effects were noticed in the mice. The
nanoscale silicon particles with added TEMPO performed favorably compared to
microscale silicon control samples, and 29Si T1 values for the nanoparticle
samples with TEMPO varied from 15-35 minutes. High resolution 29Si MR images
could be achieved over 65 minutes post-DNP.Conclusions
We demonstrate that adding exogenous radicals to nano-scale silicon
particles significantly improves their hyperpolarization characteristics to
allow in vivo 29Si MRI. Future studies will attach targeting agents and
therapeutic drugs to allow multiplexed theranostics using nanoscale silicon.Acknowledgements
Acknowledgements: This work was funded by the MDACC Odyssey Postdoctoral Fellowship, NCI R25T
CA057730, DoD PC131680, MDACC Institutional Research Grants, MDACC Institutional
Startup, U54 CA151668, Leukemia and Brain SPORE Developmental Research Awards,
NCI R21 CA185536, Gulf Coast Consortium, CPRIT RP150701, and NCI Cancer Center
Support Grant CA016672.References
[1] Park, et al. Nat. Mat.
(2009)
[2] Tasciotti, et al. Nat.
Nano. (2008)
[3] Cassidy, et al.
Nat. Nano. (2013)
[4] Dementyev, et al.
Phys. Rev. Lett. (2008)
[5] Whiting, et
al. J. Med. Imag. (2016 )
[6] Atkins, et
al., ACS Nano (2013)
[7] Kwiatkowski, et
al., Sci. Rep. (2017).